ADAMTS13: Definition and Clinical Significance
ADAMTS13 is a plasma metalloprotease enzyme (A Disintegrin and Metalloproteinase with ThromboSpondin type 1 motifs, member 13) that cleaves ultra-large von Willebrand factor (UL-VWF) multimers to prevent excessive platelet aggregation and microvascular thrombosis 1.
Biological Function
ADAMTS13 is produced primarily in:
- Hepatic stellate cells (main source)
- Endothelial cells (secondary source)
Once released into the bloodstream, ADAMTS13 performs critical hemostatic regulation by:
- Cleaving ultra-large VWF multimers into smaller, less thrombogenic forms
- Preventing excessive platelet adhesion and aggregation at sites of vascular injury
- Regulating inflammatory responses 1, 2
Clinical Significance
Severe Deficiency (<10% Activity)
When ADAMTS13 activity falls below 10% of normal, it causes thrombotic thrombocytopenic purpura (TTP), a life-threatening condition characterized by:
- Severe thrombocytopenia (usually <30 × 10⁹/L)
- Microangiopathic hemolytic anemia
- Microvascular thrombus formation throughout the body
- End-organ ischemic damage and potential mortality 1, 2
Two Forms of Deficiency
Immune TTP (iTTP):
- Caused by autoantibodies against ADAMTS13
- Most common form
- Requires detection of anti-ADAMTS13 IgG antibodies (though absence doesn't rule out iTTP) 1
Congenital TTP (cTTP):
- Caused by inherited mutations in the ADAMTS13 gene
- Approximately 250 causative mutations identified
- Usually compound heterozygous, occasionally homozygous
- Requires genetic testing for confirmation 1, 2
Diagnostic Utility
ADAMTS13 activity <10 IU/dL (or 10% of normal) in the proper clinical context confirms TTP diagnosis and distinguishes it from other thrombotic microangiopathies 1, 2. This measurement is mandatory for TTP diagnosis, though treatment must often begin before results are available due to turnaround time delays 2.
Therapeutic Implications
The 2025 ISTH guidelines now strongly recommend recombinant ADAMTS13 replacement therapy for patients with cTTP in remission, representing a major advancement over traditional fresh frozen plasma therapy 1.